| Literature DB >> 35764207 |
Haisu Yi1, Qian Wang1, Jiankai Deng2, Hengchun Li3, Yingkun Zhang4, Zhilong Chen5, Tianxin Ji6, Wenming Liu7, Xuehua Zheng7, Qinghua Ma2, Xinxin Sun7, Yudi Zhang3, Xuegao Yu2, Mengzhang He6, Ling Chen8, Ying Feng9.
Abstract
Human adenoviruses type 26 (HAdV26) and type 35 (HAdV35) have increasingly become the choice of adenovirus vectors for vaccine application. However, the population pre-existing immunity to these two adenoviruses in China, which may reduce vaccine efficacy, remains largely unknown. Here, we established micro-neutralizing (MN) assays to investigate the seroprevalence of neutralizing antibodies (nAbs) against HAdV26 and HAdV35 in the general population of Guangdong and Shandong provinces, China. A total of 1184 serum samples were collected, 47.0% and 15.8% of which showed HAdV26 and HAdV35 nAb activity, respectively. HAdV26-seropositive individuals tended to have more moderate nAbs titers (201-1000), while HAdV35-seropositive individuals appeared to have more low nAbs titers (72-200). The seropositive rates of HAdV26 and HAdV35 in individuals younger than 20 years old were very low. The seropositive rates of HAdV26 increased with age before 70 years old and decreased thereafter, while HAdV35 seropositive rates did not show similar characteristics. Notably, the seropositive rates and nAb levels of both HAdV26 and HAdV35 were higher in Guangdong Province than in Shandong Province, but did not exert significant differences between males and females. The seroprevalence between HAdV26 and HAdV35 showed little correlation, and no significant cross-neutralizing activity was detected. These results clarified the characteristics of the herd immunity against HAdV26 and HAdV35, and provided information for the rational development and application of HAdV26 and HAdV35 as vaccine vectors in China.Entities:
Keywords: Guangdong and shandong provinces; Human adenovirus type 26 (HAdV 26); Human adenovirus type 35 (HAdV 35); Neutralizing antibody (nAb); Seroprevalence
Mesh:
Substances:
Year: 2022 PMID: 35764207 PMCID: PMC9583180 DOI: 10.1016/j.virs.2022.06.006
Source DB: PubMed Journal: Virol Sin ISSN: 1995-820X Impact factor: 6.947